What is EBOO and how does it actually work?
EBOO — Extracorporeal Blood Oxygenation and Ozonation — combines two distinct mechanisms in a single continuous treatment. Blood is drawn through a dialysis-grade filter that removes circulating inflammatory proteins, lipid peroxidation products, and immune complexes. Simultaneously, the filtered blood passes across an ozone exchange membrane where medical-grade ozone (O₃) reacts with plasma lipids and proteins to form reactive oxygen species (ROS) and lipid oxidation products (LOPs). These second-messenger molecules drive the therapeutic response after the ozone itself has metabolized within seconds.
At the cellular level, controlled oxidative stress activates Nrf2 — the master regulator of antioxidant gene expression. Within hours, the body upregulates glutathione synthesis, superoxide dismutase, catalase, and heme oxygenase-1 (HO-1). The result is a sustained increase in endogenous antioxidant capacity that outlasts the treatment by weeks. This is the mechanism first characterized by Bocci in the 1990s and confirmed by subsequent mechanism papers (Sagai & Bocci, 2011).
EBOO differs from other ozone modalities in dose and contact time. Standard major autohemotherapy (MAH) treats roughly 200 mL of blood once. Ten-pass therapy repeats this ten times within the same session. EBOO maintains continuous ozone exposure across the entire circulating blood volume over a 60–90 minute treatment — the highest-dose modality in current clinical use.
What conditions is EBOO most-studied for?
The strongest published applications fall in three categories: post-acute infectious states (chronic Lyme disease, post-viral fatigue syndromes, long-COVID), autoimmune conditions with oxidative-stress components (rheumatoid arthritis, fibromyalgia, systemic lupus when stable), and adjunctive use in select oncology protocols under separate oncologist supervision. Smaller studies have examined EBOO in refractory chronic fatigue, complex regional pain syndrome, and peripheral arterial disease.
Tirelli's 2018 case series of 65 fibromyalgia patients treated with ozone autohemotherapy reported clinically meaningful symptom reduction in 70% of subjects. Smith et al. (2017) reviewed the broader pharmacodynamics and identified consistent immune-modulatory effects across published studies. The Nrf2/HO-1 pathway described by Sagai and Bocci ties oxidative preconditioning to systemic anti-inflammatory effects.
- ◇Chronic Lyme disease and post-treatment Lyme syndrome — Adjunct to standard antimicrobial protocols
- ◇Post-viral fatigue (including long-COVID)
- ◇Autoimmune dysregulation with oxidative-stress components
- ◇Refractory chronic fatigue and fibromyalgia
- ◇Athletic recovery and performance optimization
- ◇Adjunctive use in select oncology protocols — Under separate oncology supervision
Who should not have EBOO therapy?
Absolute contraindications must be ruled out before scheduling. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most important — ozone-induced oxidative stress can trigger acute hemolysis in G6PD-deficient patients. We screen every first-time EBOO patient with a quantitative G6PD assay.
Other absolute contraindications include pregnancy, active hemorrhage, uncontrolled hyperthyroidism, recent myocardial infarction (within 90 days), and recent stroke. Relative contraindications requiring individual physician assessment include severe anemia (hemoglobin under 9 g/dL), uncontrolled hypertension, severe coagulopathy, active medullary thyroid carcinoma, and current anticoagulation that cannot be safely held for IV access.
Every first-time patient completes a baseline CBC, comprehensive metabolic panel, G6PD assay, and pregnancy test when applicable. Patients on warfarin or direct oral anticoagulants (DOACs) are reviewed with their prescribing physician before scheduling.
What does an EBOO session look like, step by step?
A first session begins with bilateral IV access — one draw line, one return line. The blood is heparinized through the circuit to prevent clotting and runs through the filter and ozone exchange membrane continuously. Throughout the procedure, oxygen saturation, blood pressure, and patient comfort are monitored under direct physician supervision.
Patients rest in a treatment recliner; most read, work on a laptop, or sleep through the treatment. Total clinic time is typically 90–120 minutes — IV placement (15–20 minutes), the active treatment (60–90 minutes), and post-treatment observation (15–20 minutes). The procedure itself is painless aside from initial IV insertion.
- 01Intake and baseline labs reviewed — Required only for first session
- 02Bilateral IV access established under sterile technique
- 03Continuous blood filtration begins — Dialysis-grade membrane removes inflammatory proteins and LOPs
- 04Ozone exchange runs in parallel for 60–90 minutes
- 05Continuous vital-sign monitoring throughout the procedure
- 06Post-treatment observation for 15–20 minutes
- 07Hydration recommendations and follow-up scheduling
What does recovery look like after EBOO?
There is no formal recovery period. Most patients return to normal activity the same day. Many report increased energy and mental clarity during or immediately after the session — this is the acute Nrf2 response. Some patients experience mild fatigue lasting 6–24 hours, particularly after the first session, as the body upregulates its antioxidant response. This resolves without intervention.
Hydration is the most important post-treatment factor. We recommend 24–32 oz of water within the first hour and continued generous hydration through the day. Strenuous exercise within 6 hours is discouraged. Most patients schedule their first session on a day when they can rest if needed and report progressively easier sessions thereafter.
How is EBOO different from other ozone therapies?
Compared to ten-pass ozone, EBOO delivers continuous ozone exposure rather than discrete progressive pulses, and adds plasma filtration that ten-pass does not. Compared to single-dose major autohemotherapy, total ozone exposure is roughly an order of magnitude higher. Compared to insufflations (rectal, vaginal, ear), EBOO delivers a systemic dose comparable to other intravenous methods while avoiding mucosal exposure and dose ambiguity.
Clinical choice depends on condition severity, patient tolerance, and prior treatment response. We typically reserve EBOO for high-acuity presentations, patients who have not responded to lower-dose modalities, or cases where the dialysis-grade filtration component is clinically valuable. Lower-acuity wellness goals are often well-served by single-pass MAH or ten-pass without escalating to EBOO.
How many sessions are typically required?
Acute applications — recovery from a viral illness, athletic performance preparation, or post-surgical inflammation — often respond to a single session or a short series of 2–3. Chronic conditions typically require a more sustained protocol.
For chronic Lyme, post-viral syndromes, and refractory fibromyalgia, the most common initial protocol is 4–8 sessions over 2–3 months, followed by maintenance every 2–3 months as needed. Some patients with severe presentations benefit from a more intensive opening series of 8–10 sessions over 6 weeks before transitioning to maintenance spacing.
Response is reassessed at the 4-session mark using patient-reported outcomes, inflammatory marker trends (hs-CRP, ESR, ferritin), and any condition-specific labs. Patients who show no measurable response after four properly-dosed sessions are reviewed for protocol revision or alternative therapy.